Development of the quinolones
|
|
- Coleen Nichols
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2003) 51, Suppl. S1, 1 11 DOI: /jac/dkg212 Development of the quinolones Monique I. Andersson and Alasdair P. MacGowan* Bristol Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK Introduction Since their discovery in the early 1960s, the quinolone group of antibacterials has generated considerable clinical and scientific interest. Nalidixic acid, the first quinolone to be developed, was obtained as an impurity during the manufacture of quinine. Since this time, many derivatives have been synthesized and evaluated for their antibacterial potency. Two major groups of compounds have been developed from the basic molecule: quinolones and naphthyridones. Manipulations of the basic molecule, including replacing hydrogen with fluorine at position 6, substituting a diamine residue at position 7 and adding new residues at position 1 of the quinolone ring, have led to enhanced antibacterial efficacy. In general these compounds are well tolerated. However, some of these structural changes have been found to correlate with specific adverse events: the addition of fluorine or chlorine at position 8 being associated with photoreactivity, e.g. Bay y 3118 and sparfloxacin; and the substitution of an amine or a methyl group at position 5 having a potential role in QTc prolongation, e.g. sparfloxacin and grepafloxacin. Progressive modifications in molecular configuration have resulted in improved breadth and potency of in vitro activity and pharmacokinetics. One of the most significant developments has been the improved anti-gram-positive activity of the newer compounds, such as moxifloxacin and garenoxacin. In the current millennium, these new agents may play an important role in the treatment of respiratory infections. Keywords: quinolones, pharmacokinetics, pharmacodynamics, drug development Quinolones have been the centre of considerable scientific and clinical interest since their discovery in the early 1960s. This is because they potentially offer many of the attributes of an ideal antibiotic, combining high potency, a broad spectrum of activity, good bioavailability, oral and intravenous formulations, high serum levels, a large volume of distribution indicating concentration in tissues and a potentially low incidence of side-effects. Much research has attempted to make these potential attributes real. Nalidixic acid was the first quinolone to be developed (Table 1), but it took more than a decade before additional compounds, such as flumequin, norfloxacin and enoxacin became available for clinical use. The main use for all these agents was the treatment of urinary tract infection. In the late 1980s more systemically active drugs, such as ciprofloxacin and ofloxacin, were marketed. Recently, there has been a considerable increase in the number of agents that are in development, and to date over molecules have been patented. This review will trace the development of quinolones from their sole use as treatment for urinary tract infections, via systemic use, to those agents whose primary use is for the treatment of respiratory tract infections. This development may be described in terms of structures, potency, pharmacokinetics and pharmacodynamics, and finally indications and clinical use. Structural developments Quinolones were derived from quinine. Figure 1 shows the basic fluoroquinolone molecule or pharmacore. 1 The addition of a fluorine molecule at position 6 was one of the earliest changes to the structure. This single alteration provides a more than 10-fold increase in gyrase inhibition and up to 100-fold improvement in MIC. Two major groups have been developed from the basic structure: quinolones and naphthyridones. 1 5 The presence of a nitrogen at position 8 identi-... *Corresponding author. Tel: ; Fax: ; alasdair.macgowan@north-bristol.swest.nhs.uk The British Society for Antimicrobial Chemotherapy
2 Table 1. Chronology of quinolones that reached the UK market M. I. Andersson and A. P. MacGowan Date Quinolone nalidixic acid cinoxacin norfloxacin ciprofloxacin, ofloxacin temafloxacin, sparfloxacin grepafloxacin, levofloxacin, trovafloxacin moxifloxacin, possibly gemifloxacin and garenoxacin in 2003 or later Figure 2. Modifications of quinolone structures: norfloxacin. In all subsequent molecules, except garenoxacin, fluorine was retained at position 6. A six-membered ring at position 7 is found in ciprofloxacin, temafloxacin, sparfloxacin, ofloxacin and levofloxacin. Figure 1. Structure of the quinolone and napthyridone molecule. In molecules where X is a carbon atom, the molecule is a quinolone (cinoxacin, norfloxacin, ofloxacin, ciprofloxacin, temafloxacin, sparfloxacin, grepafloxacin, levofloxacin, clinafloxacin, moxifloxacin, gatifloxacin). Where X is a nitrogen atom the molecule is a naphthyridone (nalidixic acid, enoxacin, tosufloxacin, trovafloxacin, gemifloxacin). Adapted from Domagala (1994). 2 fies the naphthyridones, a carbon and associated group at position 8 identifies the quinolones. 1 5 The quinolones and napththyridones were further enhanced by the addition of groups to the N 1, C-5 and C-7 positions of their respective basic molecules. The addition of piperazine to the C-7 position (e.g. norfloxacin) improves activity against Gram-negative organisms. There are data to suggest that a piperazine ring may play a role in inhibiting efflux mechanisms, thereby improving the potency of these drugs. The structure of norfloxacin illustrates these developments and subsequent to this all quinolones (except garenoxacin) have a fluorine at position 6 and many have six-membered rings at position C-7 (Figure 2). The presence of a pyrrolodinyl group at position C-7 (e.g. clinafloxacin) improves activity against Figure 3. Modification of quinolone structures: ciprofloxacin. A cyclopropyl group at position 1 is found in sparfloxacin, grepafloxacin, clinafloxacin, gatifloxacin, moxifloxacin and garenoxacin. Figure 4. Modification of quinolone structures: moxifloxacin. A fivemembered ring or azabiocyclo rings at position 7 are found in clinafloxacin and trovafloxacin (five-membered ring) or moxifloxacin and garenoxacin (azabicyclo rings). A methoxy group at position 8 is found in moxifloxacin and gatifloxacin. A difluoromethyl ether (OHF 2 ) group is found at position 8 in garenoxacin. Gram-positive organisms. In addition to piperazine at the C-7 position, a cyclopropyl group was introduced to the N 1 position and is best exemplified by ciprofloxacin, which was first synthesized in 1983 (Figure 3). This increases the potency of the drug and many subsequent quinolones have a cyclopropyl group (e.g. grepafloxacin, moxifloxacin, gatifloxacin and garenoxacin; Figure 4). The addition of a 2,4-difluorophenyl group at position 1 (e.g. trovafloxacin) also improves potency, especially in improving activity against anaerobes. A number of other structural manipulations have been tried to improve the anti-gram-positive activity of fluoroquinolones. One of the first additions was an NH 2 group at position 2
3 Development of the quinolones C-5, which resulted in a general increase in anti-gram-positive activity. This is seen with sparfloxacin which otherwise has a very similar structure to ciprofloxacin. Sparfloxacin also has a fluorine at position C-6, a piperazine at position C-7 and is alkylated. Grepafloxacin is also substituted at position C-5 but by a CH 3 group and has improved anti-gram-positive potency compared with ciprofloxacin. The substituents at position C-7 are associated with a number of key attributes, such as antibacterial spectrum, bioavailability and side-effects. The most common substituents are cyclic amino groups, for example piperazine or pyrrolidine rings; other groups have been less successful. Piperazine rings are particularly common (e.g. norfloxacin, enoxacin or ciprofloxacin) and confer potency against Gram-negative bacteria. The addition of methyl groups can improve both oral absorption and in vivo activity. However, the improved activity against Gram-positive bacteria can sometimes be at the expense of activity against Pseudomonas aeruginosa. Pyrrolidine rings (five-membered) are also common substituents at position 7, and are associated with enhanced potency against Gram-positive bacteria. However, this group is associated with low water solubility and low oral bioavailability so in vivo activity may be compromised. Introduction of methyl groups on the pyrrolidine ring helps to overcome some of these physical properties. Gemifloxacin, a naphthyridone, is a good example of the advantages and disadvantages associated with a pyrrolidine ring at position 7. 6 The addition of azabicyclo groups onto position 7 has resulted in agents (moxifloxacin and trovafloxacin) with significant anti-grampositive activity, marked lipophilicity and half-lives of >10 h. 7,8 Manipulation of the group at position 8 has also been shown to play a role in altering oral pharmacokinetics, broadening the spectrum of activity and reducing the selection of mutants Whilst alkylation has been shown to increase further anti-gram-positive activity, it also improves tissue penetration and extends the half-life by increasing lipophilicity, as with grepafloxacin, levofloxacin and sparfloxacin. The structural changes to the quinolone molecule and correlation with adverse events are now well documented. 3,14 Photo-reactivity is probably most influenced by position 8, with fluorine or chlorine producing most phototoxic potential (e.g. lomefloxacin, clinafloxacin, Bay y 3118 and sparfloxacin) and methoxy groups the least (e.g. moxifloxacin or gatifloxacin). Garenoxacin has fluorine incorporated through a C-8 difluoromethyl ether linkage as there is no fluorine at C-6. It has been suggested that substitution at position 5 may have a role in QTc prolongation as those agents that have been associated with significant problems, such as sparfloxacin and grepafloxacin, have either a NH 2 or a CH 3 group in this position. 15,16 Much speculation has also surrounded the likely structural correlates of the haemolytic uraemic-like syndrome caused by temafloxacin, 17 hepatic eosinophilia caused by trovafloxacin, 18 pulmonary interstitial eosinophilia and other immunological side-effects caused by tosufloxacin 19 and gemifloxacin, and the hypoglycaemia seen with temafloxacin and clinafloxacin. 18,20,21 Although a number of these agents are naphthyridones (trovafloxacin, tosufloxacin and gemifloxacin) others are fluoroquinolones (temafloxacin), hence it is unclear whether this difference is relevant. A more powerful association is that of the 2,4-difluorophenyl group at position 1, as this is shared by trovafloxacin, temafloxacin and tosufloxacin 1 but not by gemifloxacin. 6 A further hypothesis is that metabolites of these agents (as yet not fully identified), which share common structures, may be responsible for some of the immunologically mediated adverse events seen with these drugs. The naphthyridones can be modified by the addition of cyclopropyl groups in the same way as the quinolones. A fivemembered ring has been added to the molecule of gemifloxacin at position 7. Trovafloxacin has an azabicyclo ring, which improves anti-gram-positive activity, increases the half-life and results in resistance to efflux pumps. 8 Developments in potency The development of these agents can be described in terms of their potency against Gram-positive, Gram-negative or atypical bacteria. In terms of anti-gram-negative potency, as indicated by MIC 90 s, the activity of quinolones against Enterobacteriaceae such as Escherichia coli and Klebsiella spp. has not changed significantly since the development of norfloxacin (Table 2). 6,22 31 In terms of their MIC 90 s, the early drugs (nalidixic acid and cinoxacin) did not have very good anti-pseudomonal potency. In general, the newer agents have improved activity against pathogens such as Mycoplasma pneumoniae and other atypical bacteria, and some have improved activity against Gram-negative anaerobes, such as Bacteroides fragilis (Tables 2 and 3). However, many of the newer agents, such as gatifloxacin, gemifloxacin, garenoxacin and moxifloxacin, are not as potent as ciprofloxacin against P. aeruginosa. One of the more interesting developments in terms of potency is the area of anti-gram-positive activity. Although it is unlikely any fluoroquinolone will have activity against ciprofloxacin-resistant Staphylococcus aureus, a major development has been in the activity of these drugs against ciprofloxacin-sensitive S. aureus, Streptococcus pneumoniae and Group A streptococci. 10,12,32 35 This is one of the key advances in terms of the development of these agents. Table ,36 39 lists the fluoroquinolones on the basis of their MIC 90 s for five Gram-positive species. Nalidixic acid, cinoxacin and enoxacin have no activity at all, whereas gemifloxacin has an MIC 90 of 0.03 mg/l for S. pneumoniae, and is 3
4 M. I. Andersson and A. P. MacGowan Table 2. Development of quinolone potency against Gram-negative bacteria MIC 90 (mg/l) Quinolone E. coli Klebsiella spp. Enterobacter/ Citrobacter spp. Serratia spp. Haemophilus influenzae P. aeruginosa B. fragilis Nalidixic acid 8 16 >64 >64 2 >64 >64 Cinoxacin 8 8 >64 >64 2 >64 >64 Enoxacin >64 Norfloxacin >64 Ciprofloxacin Ofloxacin Levofloxacin Temafloxacin Trovafloxacin Clinafloxacin Sparfloxacin Grepafloxacin Moxifloxacin Gatifloxacin Gemifloxacin ND Garenoxacin Table 3. Development of quinolone potency against atypical bacteria Quinolone Legionella pneumophila MIC 90 (mg/l) M. pneumoniae Chlamydia spp. Mycoplasma hominis Ureaplasma urealyticum Nalidixic acid 0.25 >64 >64 >64 >64 Enoxacin Norfloxacin Ciprofloxacin Ofloxacin Levofloxacin Trovafloxacin Clinafloxacin Sparfloxacin Grepafloxacin Moxifloxacin Gatifloxacin Gemifloxacin Garenoxacin equivalent to the earlier compounds in terms of activity against the majority of Gram-negatives (Table 2). The activity against enterococci is less clearly defined because different species are often classified together, and the proportions of Enterococcus faecium and Enterococcus faecalis are not provided. This is important as E. faecium is more resistant than E. faecalis. Developments in pharmacodynamics and pharmacokinetics Pharmacokinetics (PK) refers to changes in drug concentration as the drug moves through the body, whilst pharmacodynamics (PD) refers to how the drug action changes with concentration or dose. 4
5 Development of the quinolones Table 4. Development of quinolone potency against Gram-positive bacteria MIC 90 (mg/l) Quinolone S. aureus (methicillin sensitive) S. pneumoniae Group A streptococci Enterococcus spp. Clostridium perfringens Nalidixic acid >64 >64 >64 >64 >64 Cinoxacin >64 >64 >64 >64 >64 Enoxacin >64 Ciprofloxacin Ofloxacin Levofloxacin Temafloxacin Sparfloxacin Grepafloxacin Gatifloxacin Trovafloxacin Moxifloxacin Clinafloxacin Gemifloxacin ND Garenoxacin Table 5. Development of quinolone pharmacokinetics Quinolone Dose (g) (frequency per day) C max (mg/l) AUC (mg h/l) Half-life (h) Protein binding (%) Elimination route Nalidixic acid 1 ( 4) variable variable renal Enoxacin 0.5 ( 2) renal Enoxacin 0.6 ( 1) renal Norfloxacin 0.4 ( 2) renal and hepatic Ciprofloxacin 0.75 ( 2) renal and enteral Ofloxacin 0.4 ( 2) renal Levofloxacin 0.5 ( 1) renal Temafloxacin 0.6 ( 2) renal Trovafloxacin 0.3 ( 1) hepatic Clinafloxacin 0.2 ( 2) renal Sparfloxacin 0.4 ( 1) renal and hepatic Grepafloxacin 0.4 ( 1) hepatic Moxifloxacin 0.4 ( 1) hepatic Gatifloxacin 0.4 ( 1) renal Gemifloxacin 0.32 ( 1) renal and other Garenoxacin 0.4 ( 1) renal and other Nalidixic acid is a drug that is excreted in urine and has very variable systemic absorption. Essentially it is not a systemic drug, but a urinary agent. Over time, larger serum area under the curve (AUC) or peak serum (C max ) values are consistently seen as the quinolones have developed, and oral absorption has markedly improved compared with that of nalidixic acid (Table 5). 6,30,31,40,41 The half-life of these agents has also tended to increase as structural modifications have been made to the molecule. However, since the activity of quinolones is concentration dependent, meaning that the extent of bacterial killing increases as drug concentrations increase, and they have a prolonged post-antibiotic effect (PAE), 42 a long halflife is not an absolute prerequisite for once-daily dosing. 14,43,44 No trend in protein binding has become apparent over time with some agents having a binding of <30% (norfloxacin, temafloxacin and gatifloxacin) and others >70% (nalidixic 5
6 M. I. Andersson and A. P. MacGowan Table 6. Development of quinolone pharmacodynamics against Gram-negative pathogens AUC/MIC (total) E. coli H. influenzae P. aeruginosa <12.5 nalidixic acid nalidixic acid nalidixic acid, enoxacin, norfloxacin, sparfloxacin, grepafloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin enoxacin, ofloxacin ciprofloxacin, levofloxacin, trovafloxacin, clinafloxacin norfloxacin >100 all others all others temafloxacin Table 7. Development of quinolone pharmacodynamics against Gram-positive pathogens AUC/MIC (total) S. aureus S. pneumoniae Group A streptococci <12.5 nalidixic acid, cinoxacin, norfloxacin acid, enoxacin, trovafloxacin and garenoxacin). Non-renal clearance seems to have become a feature of a number of the newer agents (e.g. trovafloxacin, grepafloxacin, moxifloxacin and garenoxacin), although many fluoroquinolones and naphthyridones are eliminated primarily by metabolism and renal clearance (glomerular filtration and active tubular secretion). Clearly, a high free-drug C max and AUCs, combined with lower MIC, are a significant advance because they will have the effect of increasing the value of C max /MIC or AUC/MIC ratios. There is always a certain amount of debate as to whether the C max /MIC or the AUC/MIC is more important in terms of fluoroquinolone bacteriological and clinical outcomes in man. This is probably not important because the co-variable nature of these two pharmacokinetic parameters makes it difficult to identify which one is dominant in determining microbiological and clinical outcome. In general, agents with large AUC also have high C max concentrations. The other area of considerable pharmacodynamic debate has been what breakpoint or critical PK/PD ratio is required to optimize microbiological or clinical outcomes. For example, if there is a range of values, the bigger numbers are more likely to be predictive of good clinical outcome in terms of the microbiology nalidixic acid, cinoxacin, enoxacin, norfloxacin nalidixic acid, cinoxacin, enoxacin, norfloxacin enoxacin ciprofloxacin sparfloxacin, grepafloxacin ciprofloxacin ofloxacin, levofloxacin, grepafloxacin ciprofloxacin, ofloxacin, levofloxacin sparfloxacin >100 ofloxacin, levofloxacin, temafloxacin, trovafloxacin, clinafloxacin, grepafloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin temafloxacin, trovafloxacin, clinafloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin temafloxacin, trovafloxacin, clinafloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin and the emergence of resistance. 45 At present it is reasonable to assume that almost all the drugs that have AUC/MIC ratios >100 are likely to have useful activity against Enterobacteriaceae and P. aeruginosa, while a target of free AUC/MIC of is required for S. pneumoniae. 46 For predicting efficacy against most infections, pharmacodynamic variables (for example, AUC/MIC or C max /MIC) are driven by changes in potency, much more than they are driven by changes in pharmacokinetics. The MIC changes are sometimes 100-fold between agents, whereas the pharmacokinetic changes are probably at most five-fold between any of these agents. For example, as ciprofloxacin has an AUC/MIC between 25 and 50 for the therapy of P. aeruginosa, it can be anticipated that levofloxacin, trovafloxacin and clinafloxacin will have similar activity to ciprofloxacin against P. aeruginosa (Table 6). 47,48 In contrast, some of the newer drugs, such as grepafloxacin, moxifloxacin, gatifloxacin, sparfloxacin, gemifloxacin or garenoxacin, together with some of the older urinary drugs like norfloxacin, are unlikely to have significant clinical activity against P. aeruginosa at present doses. Pharmacodynamics would predict that all but the very early quinolones will have good clinical activity 6
7 Table 8. Proposed classification of fluoroquinolones Development of the quinolones Agents Activity Clinical applications Urinary agents ( ) nalidixic acid cinoxacin enoxacin norfloxacin Gram-negative systemic agents ( ) ciprofloxacin ofloxacin levofloxacin Broad spectrum systemic agents ( ) temafloxacin clinafloxacin trovafloxacin Respiratory agents (1995 onwards) levofloxacin sparfloxacin grepafloxacin moxifloxacin gatifloxacin gemifloxacin garenoxacin against E. coli and H. influenzae causing systemic infection (Table 6). With respect to the Gram-positive organisms, it is clear that the urinary drugs are not going to have useful clinical activity against S. pneumoniae, S. aureus or Streptococcus pyogenes (Table 7). Whereas with ofloxacin, levofloxacin, grepafloxacin and sparfloxacin, AUC/MIC ratios of >25 are beginning to predict clinically useful outcomes for non-immunocompromised patients with mild to moderate communityacquired disease. In the context of immunocompromised patients (those with co-morbidity or ITU patients) or in order to prevent the emergence of resistance, ratios should probably be higher. The more recently developed fluoroquinolones, such as trovafloxacin, gatifloxacin, gemifloxacin, moxifloxacin and garenoxacin, are likely to have useful clinical activity against S. pneumoniae, a prediction now supported by clinical trials data in community-acquired pneumonia 49 and acute exacerbation of chronic bronchitis (AECB). 50,51 The small amount of existing clinical data also implies that these agents are clinically active against ciprofloxacin-susceptible S. aureus and Group A streptococci ,52 activity against common Enterobacteriaceae, short serum half-lives, renal elimination wide activity against Gram-negatives, including P. aeruginosa, marginal activity against Gram-positives, longer serum half-lives wide activity against Gram-negatives, including P. aeruginosa for some agents, and Gram-positives, for some agents long serum half-lives, some activity against anaerobes wide activity against Enterobacteriaceae, active against Gram-positives, especially S. pneumoniae, active against atypical bacteria, variable activity against anaerobes, long serum half-life Toxicology Many of the more recently developed quinolones do not have the toxicological disadvantages of the earlier compounds, for example the QTc prolongation that has limited the use of sparfloxacin and grepafloxacin. Other effects include a haemolytic uraemic-like syndrome with temafloxacin, 17 a metallic taste with grepafloxacin, 53 hepatitis with trovafloxacin, 54 unexpected hypoglycaemia with clinafloxacin and temafloxacin, 21,55,56 a number of immunologically mediated adverse events with tosufloxacin, 18 and an immune-mediated rash in young women with gemifloxacin. 6 To date there are little toxicological data on garenoxacin. Indications and use main use in UTI widely used against tissue-based and urinary infections widely used against a broad range of tissuebased infections main use in respiratory tract infection The pharmacokinetic and in vitro potency profiles of fluoroquinolones determine the areas of clinical use. This has shifted from agents used predominantly for the treatment of urinary tract infections in the 1960s/70s, to more systemic use in the 1980s/90s, and in the current millennium, to the treatment of respiratory tract infections. Sparfloxacin and grepa- 7
8 M. I. Andersson and A. P. MacGowan Figure 5. Development of quinolones. floxacin were the first agents to focus on the respiratory tract, exploiting their activity against S. pneumoniae and atypical organisms. More recently a further group of agents (moxifloxacin, gatifloxacin, gemifloxacin and garenoxacin) with more convincing potential in the respiratory tract have been developed. Thus development has moved from the urinary to the respiratory tract via a miscellaneous group of systemic indications. Levofloxacin is one example of a drug where there is a wide range of potential uses, but in terms of marketing the main focus appears to be respiratory. On this basis, quinolones can be classified into four groups according to clinical use, potency, pharmacokinetics and pharmacodynamics. The first group consists of urinary agents that are, in general, the older drugs which are active against the common Enterobacteriaceae and tend to have short halflives and renal elimination (Table 8). The second group includes the anti-gram-negative systemic agents such as ciprofloxacin, levofloxacin and ofloxacin which, according to their pharmacokinetics and activity, indicate that they can be used for Gram-negative infection and as anti-pseudomonal agents. There is, however, debate about their use in various areas of Gram-positive infection. The third group, of which trovafloxacin and temafloxacin are the best examples, have sufficiently broad activity in terms of anti-gram-negative, 8
9 Development of the quinolones anti-gram-positive, antipseudomonal and anti-anaerobic activity, to indicate their use for a wide range of tissue-based infections. The fourth group includes the respiratory agents, some of which are also in other categories. These drugs have activity against S. pneumoniae and atypical organisms, but are less active against P. aeruginosa. Some of these agents, such as moxifloxacin and garenoxacin, may be as active as trovafloxacin against anaerobes, suggesting that with time, their clinical indications may expand beyond the respiratory area. The nomenclature of the quinolones is complex, and these agents have also been classified in terms of generation 57 (discussed in this supplement in the article by P. Ball). However, whichever classification is used, it is clear that these agents are not a homogeneous group of antibiotics, and that important differences exist between them. Conclusions Modifications in the basic structure of quinolones have increased their antibacterial spectrum and potency, as well as improving bioavailability, making quinolones useful agents for the treatment of urinary, systemic and respiratory tract infections. An evolutionary tree is shown in Figure 5. However, safety concerns continue with some members of this class and have resulted in the withdrawal of some agents after marketing (temafloxacin, grepafloxacin, sparfloxacin, trovafloxacin) or others in late development (clinafloxacin and gemifloxacin). It is still unclear as to which structure function relationships have resulted in these problems, so despite a good deal of progress being made in terms of in vitro activity and pharmacodynamics, progress in the area of toxicology has been erratic. References 1. Tillotson, G. S. & Blondeau, J. M. (1999). Structure activity function evaluation of the fluoroquinolones. In Moxifloxacin in Practice (Adam, D., Finch, R. G. & Hunter, P. A., Eds), pp Maxim Medical, Oxford, UK. 2. Domagala, J. M. (1994). Structure activity and structure sideeffect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy 33, Asahina, Y., Ishizaki, T. & Suzue, S. (1992). Recent advances in structure activity relationships in new quinolones. Progress in Drug Research 38, Tillotson, G. S. (1996) Quinolones: structure activity relationships and future predictions. Journal of Medical Microbiology 44, Ball, P., Fernald, A. & Tillotson, G. (1998). Therapeutic advances of new fluoroquinolones. Expert Opinion in Investigational Drugs 7, Lowe, M. N. & Lamb, H. M. (2000). Gemifloxacin. Drugs 59, Ball, P. (2000). Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency. International Journal of Clinical Practice 54, Brighty, K. E. & Gootz, T. D. (1997). The chemistry and biological profile of trovafloxacin. Journal of Antimicrobial Chemotherapy 39, Suppl. B, Dong, Y., Xu, C., Zhao, X., Domagala, J. & Drlica, K. (1998). Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrobial Agents and Chemotherapy 42, Zhao, X., Wang, J. Y., Xu, C., Dong, Y., Zhou, J., Domagala, J. et al. (1998). Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrobial Agents and Chemotherapy 42, Lu, T., Zhao, X. & Drlica, K. (1999) Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrobial Agents and Chemotherapy 43, Cecchetti, V., Fravolini, A., Lorenzini, M. C., Tabarrini, O., Terni, P. & Xin, T. (1996). Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. Journal of Medicinal Chemistry 39, Ma, Z., Chu, D. T., Cooper, C. S., Li, Q., Fung, A. K., Wang, S. et al. (1999). Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position. Journal of Medicinal Chemistry 42, Gootz, T. D. & Brighty, K. E. (1996). Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews 16, Lipsky, B. A. & Baker, C. A. (1999). Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clinical Infectious Diseases 28, Jaillon, P., Morganroth, J., Brumpt, I. & Talbot, G. (1996). Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Journal of Antimicrobial Chemotherapy 37, Suppl. A, Blum, M. D., Graham, D. J. & McCloskey, C. A. (1994). Temafloxacin syndrome: review of 95 cases. Clinical Infectious Diseases 18, Ball, P., Mandell, L., Niki, Y. & Tillotson, G. (1999). Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 21, Yamamoto, T., Tanida, T., Ueta, E., Kimura, T., Doi, S. & Osaki, T. (2001). Pulmonary infiltration with eosinophilia (PIE) syndrome induced by antibiotics, PIPC and TFLX during cancer treatment. Oral Oncology 37, Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J. et al. (2002). A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62, Rubinstein, E. (2001). History of quinolones and their side effects. Chemotherapy 47, Suppl. 3, Dalhoff, A. (1999). In vitro activities of quinolones. Expert Opinion on Investigational Drugs 8, Reeves, D. S., Bywater, M. J. & Holt, H. A. (1984). The activity of enoxacin against clinical bacterial isolates in comparison with that
10 M. I. Andersson and A. P. MacGowan of five other agents, and factors affecting that activity. Journal of Antimicrobial Chemotherapy 14, Suppl. C, Newsom, S. W. (1984). The antimicrobial spectrum of norfloxacin. Journal of Antimicrobial Chemotherapy 13, Suppl. B, Gruneberg, R. N., Felmingham, D., O Hare, M. D., Robbins, M. J., Perry, K., Wall, R. A. et al. (1988). The comparative in-vitro activity of ofloxacin. Journal of Antimicrobial Chemotherapy 22, Suppl. C, King, A. & Phillips, I. (1986). The comparative in-vitro activity of eight newer quinolones and nalidixic acid. Journal of Antimicrobial Chemotherapy 18, Suppl. D, Wiedemann, B. & Heisig, P. (1997). Antibacterial activity of grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, Cunha, B. A., Qadri, S. M., Ueno, Y., Walters, E. A. & Domenico, P. (1997). Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. Journal of Antimicrobial Chemotherapy 39, Suppl. B, Wise, R., Ashby, J. P. & Andrews, J. M. (1988). In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrobial Agents and Chemotherapy 32, MacGowan, A. P. (1999). Moxifloxacin (Bay ): a new methoxy quinolone antibacterial. Expert Opinion on Investigational Drugs 8, Perry, C. M., Barman Balfour, J. A. & Lamb, H. M. (1999). Gatifloxacin. Drugs 58, Berrington, A. W., Koerner, R. J., Perry, J. D., Bain, H. H. & Gould, F. K. (2001). Treatment of Staphylococcus aureus endocarditis using moxifloxacin. International Journal of Medical Microbiology 291, Muijsers, R. B. & Jarvis, B. (2002). Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 62, Parish, L. C., Routh, H. B., Miskin, B., Fidelholtz, J., Werschler, P., Heyd, A. et al. (2000). Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. International Journal of Clinical Practice 54, Entenza, J. M., Que, Y. A., Vouillamoz, J., Glauser, M. P. & Moreillon, P. (2001). Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillinresistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrobial Agents and Chemotherapy 45, Bille, J. & Glauser, M. P. (1991). In-vitro activity of temafloxacin for Gram-positive pathogens. Journal of Antimicrobial Chemotherapy 28, Suppl. C, Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy 40, Suppl. A, Sefton, A. M., Maskell, J. P., Rafay, A. M., Whiley, A. & Williams, J. D. (1997). The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 39, Suppl. B, Blondeau, J. M. (1999). A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. Journal of Antimicrobial Chemotherapy 43, Suppl. B, Wolf, R., Eberl, R., Dunky, A., Mertz, N., Chang, T., Goulet, J. R. et al. (1984). The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 14, Suppl. C, Stass, H. & Kubitza, D. (1999). Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Journal of Antimicrobial Chemotherapy 43, Suppl. B, Hooper, D. (2000). Quinolones. In Mandell, Douglas, and Bennett s Principles and Practice of Infectious Diseases, 5th edn (Mandell, G. L., Bennett J. E. & Dolin, R., Eds), pp Churchill Livingstone, Philadelphia, USA. 43. Ball, P. (2000). The quinolones: history and overview. In The Quinolones, 3rd edn (Andriole, V. T., Ed.), pp Academic Press, London, UK. 44. Wise, R., Lister, D., McNulty, C. A., Griggs, D. & Andrews, J. M. (1986). The comparative pharmacokinetics of five quinolones. Journal of Antimicrobial Chemotherapy 18, Suppl. D, MacGowan, A. P. (1999). In vitro models of infection: pharmacokinetic/pharmacodynamic correlates. In Proceedings of the First International Moxifloxacin Symposium (Mandell, L., Ed.), pp Springer-Verlag, Berlin, Germany. 46. Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B. & Pierce, P. F. (2001). Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrobial Agents and Chemotherapy 45, Mouton, J. W., van Ogtrop, M. L., Andes, D. & Craig, W. A. (1999). Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrobial Agents and Chemotherapy 43, MacGowan, A. P., Wootton, M. & Holt, H. A. (1999). The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. Journal of Antimicrobial Chemotherapy 43, Patel, T., Pearl, J., Williams, J., Haverstock, D. & Church, D. (2000). Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respiratory Medicine 94, Wilson, R., Jones, P., Schaberg, T., Davey, P., Allegra, L., Izquierdo, J. L. et al. (2002). A clinical and outcomes assessment of the management of Acute Exacerbations of Chronic Bronchitis (AECB): The MOSAIC Study. In Programs and Abstracts of the Twelfth European Respiratory Society Congress, Stockholm, Abstract European Respiratory Society. 51. Wilson, R., Schentag, J. J., Ball, P. & Mandell, L. (2002). A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clinical Therapeutics 24, Worlitzsch, D., Kaygin, H., Steinhuber, A., Dalhoff, A., Botzenhart, K. & Doring, G. (2001). Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in 10
11 Development of the quinolones vitro and in vivo. Antimicrobial Agents and Chemotherapy 45, Stahlmann, R. & Schwabe, R. (1997). Safety profile of grepafloxacin compared with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 40, Suppl. A, Chen, H. J., Bloch, K. J. & Maclean, J. A. (2000). Acute eosinophilic hepatitis from trovafloxacin. New England Journal of Medicine 342, Stahlmann, R. (2002). Clinical toxicological aspects of fluoroquinolones. Toxicology Letters 127, Stratton, C. W. (1998). Pharmacokinetics, pharmacodynamics and tolerability profile of clinafloxacin. Clinical Drug Investigation 15, Suppl. 1, Ball, P. (2000). Quinolone generations: natural history or natural selection? Journal of Antimicrobial Chemotherapy 46, Suppl. T1,
12
Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationChapter 46. Sulfonamides, Trimethoprim, & Quinolones
Chapter 46 Sulfonamides, Trimethoprim, & Quinolones Classification of synthetic antimicrobial agents Ⅰ. Antifolate drugs: a. Sulfonamides b. Trimethoprim Ⅱ. DNA gyrase inhibitors: Fluoroquinolones Ⅰ. Antifolate
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationReceived 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
Journal of Antimicrobial Chemotherapy (2003) 51, 905 911 DOI: 10.1093/jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of
More information2 key enzymes in DNA replication:
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 1 Ternary
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationAUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Journal of Antimicrobial Chemotherapy (2002) 50, 533 539 DOI: 10.1093/jac/dkf177 AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationAlasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationTHE QUINOLONES. Third Edition. Edited by VINCENT T. ANDRIOLE. Yale University School of Medicine ACADEMIC PRESS
THE QUINOLONES Third Edition Edited by VINCENT T. ANDRIOLE Yale University School of Medicine ACADEMIC PRESS San Diego London Boston New York Sydney Tokyo Toronto CONTENTS Contrihuttirs Prc face xv xix
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationQuinolones A Systematic Quest
Quinolones A Systematic Quest David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Timeline of Quinolone Development orris
More informationfolate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole
Folate Antagonists Enzymes requiring folate-derived cofactors are essential for the synthesis of purines and pyrimidines (precursors of RNA and DNA) and other compounds necessary for cellular growth and
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationMechanism of action of fluoroquinolones: the basics...
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 Ternary
More information2 key enzymes in DNA replication:
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 1 Ternary
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationArchive entry. Content:
Archive entry Content: 1. Basic information about Moxifloxacin 2. History of quinolone-drugs 3. Structure of Moxifloxacin 4. 3D-structure of Moxifloxacin 5. Synthesis of Moxifloxacin 6. Biological function
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationAdvances in Fluoroquinolones Therapy
Advances in Fluoroquinolones Therapy Fluoroquinolones Synthetic antimicrobial agents with the characteristic 4- quinolone ring structure containing a fluorine moiety at the 6-position. Some members also
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationREVIEW ARTICLE. Quinolones in 2005: an update F. Van Bambeke 1, J.-M. Michot 1, J. Van Eldere 2 and P. M. Tulkens /j
REVIEW ARTICLE 10.1111/j.1469-0691.2005.01131.x Quinolones in 2005: an update F. Van Bambeke 1, J.-M. Michot 1, J. Van Eldere 2 and P. M. Tulkens 1 1 Unit of Cellular and Molecular Pharmacology, Catholic
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationSELECT NEWS. Florfenicol Monograph: Injectable & Oral Therapy for Swine
SELECT NEWS Florfenicol Monograph: Injectable & Oral Therapy for Swine Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationAppropriate Use of Quinolones in the Hospital: Is Microbiology Telling You All?
Appropriate Use of Quinolones in the Hospital: Is Microbiology Telling You All? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationReiner Schaumann, 1 Ellie J. C. Goldstein, 2 Jochen Forberg 3 and Arne C. Rodloff 1
Journal of Medical Microbiology (2005), 54, 4 53 DOI 10.10/jmm.0.454-0 Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/ pharmacodynamic model employing
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationThe Newer Fluoroquinolones
The Newer Fluoroquinolones Maureen K. Bolon, MD, MS KEYWORDS Fluoroquinolones Antiinfective agents Pharmacology Pharmacokinetics Microbial drug resistance Therapeutic use Quinolones are unusual among antimicrobials
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationUPDATES ON ANTIBIOTIC THERAPY. Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA
UPDATES ON ANTIBIOTIC THERAPY Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA ANTIBIOTICS Fluoroquinolones The fluoroquinolone class of antibiotics
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationInfection. Recently introduced antibiotics: a guide for the general physician CME: CLINICAL PRACTICE AND ITS BASIS. Linezolid.
CME: CLINICAL PRACTICE AND ITS BASIS Infection Edited by Andrew Lever MD FRCP, Professor of Infectious Diseases Addenbrooke s Hospital, Cambridge Recently introduced antibiotics: a guide for the general
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationCephalosporins, Quinolones and Co-amoxiclav Prescribing Audit
Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationSELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle
SELECT NEWS Florfenicol Monograph: Injectable Therapy for Cattle Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the lowest
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationComparative Study of the Mutant Prevention Concentration of Moxifloxacin, Levofloxacin and Gemifloxacin against Pneumococci.
AAC Accepts, published online ahead of print on 14 December 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01353-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More information